Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
 logo final copy.png)
The Hippocratic Editorial and VT team. Please send your suggestions to [email protected]
Latest posts by Hippocratic Post (see all)
- Strategies for Managing Stress and Burnout in Your Employees - 19th February 2025
- New Tool Can Detect Fast-Spreading SARS-CoV-2 Variants Early - 19th February 2025
- Cancer immunotherapy treatment dramatically reduces sunspots - 19th February 2025
